A novel cardiac output response to stress test developed to improve diagnosis and monitoring of heart failure in primary care. by Charman, Sarah J et al.
A novel cardiac output response to stress test
developed to improve diagnosis and monitoring of
heart failure in primary care
Sarah J. Charman1,3#, Nduka C. Okwose1,3#, Renae J. Stefanetti2,3, Kristian Bailey3, Jane Skinner3, Arsen Ristic4,
Petar M. Seferovic4, Mike Scott5, Stephen Turley6, Ahmet Fuat7, Jonathan Mant8, Richard F.D. Hobbs9,
Guy A. MacGowan1,3 and Djordje G. Jakovljevic1,3,10*
1Cardiovascular Research Centre, Institutes of Cellular and Genetic Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; 2Wellcome Trust
Centre for Mitochondrial Research, Institute of Neuroscience, Medical School, Newcastle University, Newcastle upon Tyne, UK; 3Royal Victoria Infirmary, Newcastle upon
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 4Cardiology Department, Clinical Centre Serbia, School of Medicine, University of Belgrade, Belgrade,
Serbia; 5Newburn Surgery, Newcastle upon Tyne, UK; 6Roseworth Surgery, Newcastle upon Tyne, UK; 7Darlington Memorial Hospital, County Durham and Darlington NHS
Foundation Trust and School of Medicine, Pharmacy and Health, Durham University, Durham, UK; 8Primary Care Unit, Department of Public Health and Primary Care,
University of Cambridge, Cambridge, UK; 9Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK; 10RCUK Centre for Ageing and Vitality,
Newcastle University, Newcastle upon Tyne, UK
Abstract
Aims Primary care physicians lack access to an objective cardiac function test. This study for the first time describes a novel
cardiac output response to stress (CORS) test developed to improve diagnosis and monitoring of heart failure in primary care
and investigates its reproducibility.
Methods and results Prospective observational study recruited 32 consecutive primary care patients (age, 63 ± 9 years;
female, n = 18). Cardiac output was measured continuously using the bioreactance method in supine and standing positions
and during two 3 min stages of a step-exercise protocol (10 and 15 steps per minute) using a 15 cm height bench. The CORS
test was performed on two occasions, i.e. Test 1 and Test 2. There was no significant difference between repeated measures of
cardiac output and stroke volume at supine standing and Stage 1 and Stage 2 step exercises (all P > 0.3). There was a
significant positive relationship between Test 1 and Test 2 cardiac outputs (r = 0.92, P = 0.01 with coefficient of variation of
7.1%). The mean difference in cardiac output (with upper and lower limits of agreement) between Test 1 and Test 2 was
0.1 (1.9 to 2.1) L/min, combining supine, standing, and step-exercise data.
Conclusions The CORS, as a novel test for objective evaluation of cardiac function, demonstrates acceptable reproducibility
and can potentially be implemented in primary care.
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Introduction
Widely considered the new epidemic of the 21st century,
heart failure is a complex clinical syndrome associated with
structural and functional cardiac abnormalities, which lead
to reduced cardiac output at rest and/or stress.1 Heart
failure increases with age and in the presence of comorbidi-
ties2,3 and is a leading cause of hospitalization in people over
65 years of age.1,2 The prevalence of cardiac dysfunction and
associated heart failure is >10% in people ≥70 years of age
and rises to >20% in those with multi-morbidities including
diabetes, coronary artery disease, metabolic syndrome,
hypertension, and rheumatoid arthritis.1 Heart failure is
associated with poor prognosis, poor quality of life for
patients, and high healthcare costs.1,2
Early diagnosis of heart failure is crucial because prompt
initiation of treatment significantly improves morbidity,
quality of life, and mortality, while reducing hospitalization
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and healthcare costs.1,4 In the absence of acute onset of
heart failure, patients commonly present to primary care
with signs and symptoms such as ankle swelling, breathless-
ness, and fatigue.2 These are non-specific and do not, there-
fore, help discriminate between heart failure and other
problems associated with age, obesity, and lung disease.3
General practitioners (GPs) have a key role in the early
identification of heart failure.3,5 However, currently available
diagnostic tools, such as electrocardiography, are insuffi-
ciently sensitive to detect heart failure.6 Although the serum
natriuretic peptides test is more accurate as a ‘rule out’ test
to exclude heart failure, it can lead to a significant number
of false positive results due to its overall reduced specific-
ity.7–9 An increased serum natriuretic peptide level is not only
found in patients with heart failure but also in those living
with chronic pulmonary disease, left ventricular systolic dys-
function, renal failure, left ventricular hypertrophy, coronary
artery disease, elderly, and obese. It is thus not surprising
that current primary care clinical practice for heart failure re-
sults in inaccurate and expensive referrals to secondary care,
which creates additional worry for the patient. It is suggested
that the majority of patients (>65%) suspected of having
heart failure by their GPs (based on symptoms, signs, and
available tests results) and referred to secondary care do
not have diagnosis confirmed following echocardiography
and heart failure specialist review.6,10–12
Heart failure continues to be misdiagnosed or
underdiagnosed in primary care because GPs lack access to
a uniform, low-cost, and patient-friendly ‘rule in’ test to objec-
tively evaluate cardiac function.7,8,13 Diagnostic uncertainty
results in diagnosis being delayed until symptoms are more
obvious and more severe, requiring multiple consultations
and hospital admissions, or people are treated incorrectly.7
The most recent definition of heart failure provided by the
European Society of Cardiology suggests that heart failure re-
sults in reduced cardiac output at rest or during stress.1 De-
spite availability of non-invasive, valid, and reliable methods
for cardiac output assessment at rest and in response to
stress,14–18 there were no recommendations from the guide-
line to incorporate measurement of cardiac output into the
heart failure diagnostic pathway.1,2 With a projected increase
in prevalence of heart failure due to an ageing population,
there will be an even greater pressure on echocardiography
and cardiology services. Therefore, there is a huge clinical de-
mand to equip GPs with a uniform, easy-to-use, low-cost, and
patient-friendly test to objectively evaluate cardiac dysfunc-
tion and improve diagnostic accuracy of heart failure in pri-
mary care. In an attempt to address this clinical demand,
we have recently developed a novel, easy-to-use, non-
invasive cardiac output response to stress (CORS) test in or-
der to improve diagnosis and monitoring of heart failure in
primary care. Prior further clinical (diagnostic and monitor-
ing) effectiveness and cost-effectiveness evaluation, it was
considered prudent firstly to describe the CORS test and
secondly to assess its reproducibility. Thus, the aim of the
present study was to describe the CORS test for the first time
and to investigate its reproducibility.
Methods
Study design, setting, and patients
The prospective observational study recruited 32 consecutive
primary care patients (14 men and 18 women; mean age
63 ± 9 years) between February and November 2017. The
study was conducted at the Clinical Research Facility of the
Royal Victoria Infirmary, Newcastle upon Tyne, UK. The inclu-
sion criteria were 50 years of age or more, no history of
chronic, cardiovascular, pulmonary, or metabolic diseases,
and willingness to visit the Clinical Research Facility. The ex-
clusion criteria were inability to independently use the stairs
and incapacity to provide written informed consent. The
study protocol (number 15/NE/0190) was approved by the
National Health Service, National Research Authority (North
East – Tyne & Wear South Research Ethics Committee). All
procedures performed in the study were in accordance with
the Declaration of Helsinki. Participants gave written in-
formed consent.
Procedures
Participants attended the clinical physiology laboratory for one
visit for approximately 2 h to complete the study (Figure 1)
and were instructed to abstain from vigorous exercise and
alcohol consumption 24 h prior to the study visit. They were
also asked to fast and not consume caffeine-containing drinks
for at least 2 h prior to the visit. Upon arrival at the laboratory,
participants were asked to complete a standardized health
screening questionnaire and physical examination to rule
out any contraindications. This was followed by anthropomet-
ric measurements (body weight and height) and a 10 min rest
period in supine position when arterial blood pressure and
electrocardiography were performed.
Study protocol and measurements
Cardiac function including cardiac output, cardiac index,
heart rate, stroke volume, stroke volume index, blood pres-
sure (systolic and diastolic), and mean arterial pressure were
recorded at rest and during exercise using the non-invasive
cardiac output monitor, based on bioreactance technology
(NICOM, Cheetah Medical, Inc., MA, USA), which we have
previously evaluated.14–16,18 This method uses four pairs of
electrodes applied at the front side of the upper and lower
thorax. Bioreactance is a novel method for continuous non-
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invasive cardiac function monitoring and estimates cardiac
output by analysing the frequency of relative phase shift of
an electronic current delivered across the thorax. The CORS
test (Figure 1) includes measurements at rest and in response
to stress (short exercise, i.e. step test). The CORS consists of
four phases: 3 min rest (supine), 3 min challenge (standing),
and two 3 min step-exercise test stages (i.e. Stage 1 step ex-
ercise, 10 steps/minute followed by Stage 2 step exercise, 15
steps/minute) using a 15 cm height bench. The online metro-
nome (TempoPerfect Metronome Software, NCH Software,
CO, USA) was used to guide participants step frequency dur-
ing the step-exercise test, i.e. 10 and 15 steps per minute. To
evaluate reproducibility of the CORS test, it was repeated
twice (referred to as Test 1 and Test 2) with at least 1 h sitting
rest between the two tests. Longer rest time was imple-
mented if participants’ resting metabolic and haemodynamic
measurements had not returned to their baseline values ob-
tained before Test 1. Simultaneously with cardiac output and
automated blood pressure measurements, gas exchange
metabolic data were also collected (i.e. oxygen consumption
and carbon dioxide production) at rest and during exercise
using the metabolic analyser (Cortex, Leipzig, Germany).
Measurement of gas exchange data was performed in order
to evaluate the metabolic demand of the CORS test.
Figure 1 Cardiac output response to stress test. The cardiac output response to stress test consists of three phases: rest, challenge, and stress exercise.
Each phase lasts for 3 min, and stress phase integrates additional 3 min to increase intensity and metabolic demand (from 10 to 15 steps per minute).
The CORS test 3
ESC Heart Failure (2018)
DOI: 10.1002/ehf2.12302
Sample size
It was estimated that recruitment of 32 study participants will
be sufficient to allow evaluation of the CORS test reproduc-
ibility. The CORS test includes three phases (rest, challenge,
and exercise, with exercise including two sub-phases). It
was calculated that the total number of assessment points
will be 128, which is obtained by multiplying 32 patients
and 4 data collection points. It was considered that 128
repeated measures of cardiac function will be sufficient to
allow detailed evaluation of the reproducibility of the CORS
test using statistical methods described in the next section.
Statistical analysis
Data were analysed using SPSS, version 24 (SPSS, Inc., Chicago,
IL, USA). The level of significance was set at P< 0.05. Data are
expressed as mean (SD). Reproducibility of haemodynamic
and metabolic variables was calculated using coefficient of
variation (CV), while linear relationships between repeated
measures were assessed using Pearson’s correlation coeffi-
cient (r). The CV was calculated as a percentage of within-
person standard deviation divided by within-person average.
A CV of ≤6% was considered as good reproducibility, while
CV of 6–10% and >10% was considered acceptable and poor
reproducibility, respectively.19 Additionally, Bland–Altman
plots were constructed to evaluate the upper and lower limits
of agreements (±2 SD of mean difference) of cardiac output
measured at rest and at different intensities of exercise.20
Results
Participant demographic and clinical characteristics are de-
tailed in Table 1. Out of 32, seven participants (22%) were
prescribed with antihypertensive medication; two were pre-
scribed with antidepressants and lipid-lowering medication.
Physical characteristics of the participants were as follows:
age 63 (range: 50–89) years, weight 71 (45–102) kg, height
165 (150–180) cm, and body mass index 26 (21–32) kg/m2.
All participants completed all phases of the CORS test with-
out any contraindication highlighting acceptability for com-
pleting this test in this study group. Excellent quality of the
signal for cardiac output measurement was obtained in 30
(97%) participants, giving a total of 126/128 data points when
data from all phases were combined. The NICOM signal was
lost for two participants during Stage 1 step exercise. Com-
plete metabolic data were obtained in 28 (88%) participants,
(112/128 data points; due to fault in the sample line causing
missing metabolic data).
There was no significant difference in resting, standing,
and step-exercise haemodynamic and metabolic data be-
tween Test 1 and Test 2 (Tables 2 and 3, respectively). At
all phases of the CORS test, there were no significant
Table 1 Participant demographics and clinical characteristics
Number of participants (N) 32
Age (years) 63 ± 9
Male, n (%) 14 (44)
Height (cm) 165 ± 8
Weight (kg) 71 ± 13
Body mass index (kg/m2) 26 ± 4
Medications N (%)
Antidepressant 2 (6)
β2 receptor agonist 1 (3)
Bile acid sequestrant 1 (3)
Angiotensin-converting enzyme inhibitor 2 (6)
Calcium channel blocker 3 (9)
Loop diuretic 1 (3)
Acetylsalicylic acid 1 (3)
Anticoagulant 1 (3)
Benign prostatic hyperplasia 1 (3)
Statins 1 (3)
Angiotensin-converting enzyme inhibitor 1 (3)
Anticholinergic 1 (3)
Table 2 Reproducibility of haemodynamic measures
Variables Test 1 Test 2 P r CV (%)
Rest
QT (L/min) 6.2 (1.4) 6.3 (1.7) 0.84 0.80 8.1
CI (L/min/m2) 3.6 (0.9) 3.6 (1.1) 0.82 0.78 9.0
HR (beats/min) 62 (7) 59 (8) 0.18 0.91 3.9
SV (mL/beat) 102 (24) 108 (32) 0.36 0.82 9.3
SVI (mL/beat/m2) 58 (14) 62 (19) 0.38 0.80 9.8
SBP (mmHg) 126 (12) 129 (15) 0.39 0.74 4.5
DBP (mmHg) 81 (11) 80 (11) 0.73 0.85 4.1
MAP (mmHg) 95 (12) 96 (11) 0.62 0.76 4.2
Standing
QT (L/min) 5.7 (2.1) 5.7 (1.9) 0.99 0.94 6.4
CI (L/min/m2) 3.3 (1.4) 3.3 (1.2) 0.96 0.95 6.5
HR (beats/min) 71 (8) 70 (9) 0.64 0.89 3.0
SV (mL/beat) 82 (32) 83 (29) 0.93 0.94 6.6
SVI (mL/beat/m2) 47 (19) 47 (18) 0.96 0.94 6.8
SBP (mmHg) 132 (17) 130 (16) 0.60 0.80 4.5
DBP (mmHg) 87 (11) 87 (10) 0.81 0.91 2.8
MAP (mmHg) 102 (11) 101 (11) 0.87 0.96 1.6
Stage 1 exercise (10 steps/minute)
QT (L/min) 8.5 (1.8) 8.2 (1.9) 0.56 0.85 6.7
CI (L/min/m2) 4.8 (1.1) 4.7 (1.2) 0.62 0.90 6.5
HR (beats/min) 83 (11) 80 (11) 0.33 0.95 3.1
SV (mL/beat) 104 (26) 104 (27) 0.99 0.89 6.1
SVI (mL/beat/m2) 59 (16) 59 (17) 0.96 0.90 6.3
SBP (mmHg) 154 (23) 143 (18) 0.05 0.88 5.6
DBP (mmHg) 84 (12) 82 (10) 0.50 0.84 4.2
MAP (mmHg) 107 (13) 102 (11) 0.12 0.88 4.3
Stage 2 exercise (15 steps/minute)
QT (L/min) 9.9 (1.7) 9.6 (2.0) 0.51 0.79 7.1
CI (L/min/m2) 5.6 (1.0) 5.5 (1.2) 0.73 0.87 6.5
HR (beats/min) 90 (12) 88 (13) 0.53 0.96 2.4
SV (mL/beat) 109 (29) 111 (26) 0.76 0.79 8.3
SVI (mL/beat/m2) 64 (14) 64 (16) 0.95 0.88 6.8
SBP (mmHg) 158 (24) 148 (21) 0.12 0.76 5.5
DBP (mmHg) 82 (12) 81 (11) 0.65 0.86 4.2
MAP (mmHg) 107 (12) 103 (12) 0.19 0.81 3.9
CI, cardiac index; CV, coefficient of variation; DBP, diastolic blood
pressure; HR, heart rate; MAP, mean arterial pressure; QT, cardiac
output; r, correlation coefficient; SBP, systolic blood pressure; SV,
stroke volume; SVI, stroke volume index.
Data are expressed as mean (SD).
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differences in either cardiac output or cardiac index values
between Test 1 and Test 2 (Figure 2A and Figure 2B). There
was a strong relationship between Test 1 and Test 2 cardiac
outputs when all phase data (rest, standing, and Stage 1
and Stage 2 step exercises) were grouped together
(r = 0.92, P = 0.01) (Figure 2C). Similarly, when all data were
grouped, a strong relationship was found between Test 1
and Test 2 for cardiac index when all data were grouped to-
gether (r = 0.92, P = 0.01) (Figure 2D).
When all data from all stages of the CORS test were com-
bined, the CVs for cardiac output, cardiac index measure-
ments, and oxygen consumption (mL/kg/min) were 7.1%,
7.0%, and 10.0%, respectively (Tables 2 and 3).
Bland–Altman analyses were performed to demonstrate
the agreement between Test 1 and Test 2 cardiac outputs
for each stage of the CORS test (Figure 3). When all data were
combined, the mean difference and lower and upper limits of
agreement between Test 1 and Test 2 cardiac outputs were
0.1 (1.9 to 2.1 L/min; Figure 5A).
Cardiac index was also not significantly different between
the two tests (as shown in Table 2 and Figure 2D) with
Bland–Altman analyses suggesting acceptable limits of
agreement (Figure 4). When all data were combined, the
mean cardiac index difference between the two tests was
0.1 L/min/m2 with lower and upper limits of agreeing
1.1 and 1.2 L/min/m2, respectively (Figure 5B).
Discussion
Statement of principal findings
The purpose of this study was to firstly describe the CORS test
and secondly to investigate its reproducibility. The major
findings of the current study suggest that the CORS test dem-
onstrated acceptable level of reproducibility. A strong posi-
tive relationship was found between repeated key measures
of the CORS test, i.e. cardiac output and cardiac index. The
calculated limits of agreement were narrow and acceptable
for each stage of the CORS test for both cardiac output and
cardiac index.
Strengths and weaknesses of the study
For the first time, the present study describes a novel CORS
test developed with the potential to improve diagnosis and
monitoring of heart failure in primary care. Haemodynamic
measurements, i.e. cardiac output and cardiac index, are
coupled with metabolic gas exchange measurements allowing
accurate determination of the CORS’ metabolic demand.
The following limitations should be considered. It was not
possible to use a gold standard method for measuring cardiac
output (i.e. thermodilution or direct Fick method) due to
their invasive approach and associated risks. Previous studies
demonstrated a positive relationship between cardiac output
estimates obtained from bioreactance and thermodilution
methods in patients undergoing surgical interventions.21,22
Secondly, although the overall sample size was small to
moderate, it should be noted that multiple measurements
and cardiac output values were obtained at different body po-
sitions as well as two different exercise intensities, which pro-
vide sufficient data points (>120) for detailed reproducibility
analysis to be performed. Lastly, the sample population did
not include patients with suspected or confirmed diagnosis of
heart failure. However, our ongoing research programme aims
to confirm clinical utility of the CORS test to improve diagnosis
and monitoring of heart failure in primary care.
Strengths and weaknesses in relation to other
studies, discussing important differences in
results
Overall, a CV of ~7% was found for both cardiac output and
cardiac index, respectively, suggesting acceptable
Table 3 Reproducibility of metabolic measurements
Variables Test 1 Test 2 P value r CV (%)
Rest
VO2 (L/min) 0.3 (0.1) 0.3 (0.1) 0.87 0.62 13.5
VO2 (mL/kg/min) 3.5 (1.0) 3.4 (1.0) 0.90 0.53 12.5
VCO2 (L/min) 0.2 (0.1) 0.2 (0.1) 0.87 0.77 11.0
RER 0.8 (0.1) 0.8 (0.1) 0.99 0.65 4.5
VE (L/min) 6.7 (2.1) 6.7 (2.4) 0.90 0.70 13.5
VE/VCO2 28.1 (2.9) 27.2 (3.5) 0.27 0.57 6.7
BF 11.8 (2.9) 11.4 (3.3) 0.61 0.43 14.4
Standing
VO2 (L/min) 0.3 (0.1) 0.3 (0.1) 0.74 0.63 14.4
VO2 (mL/kg/min) 3.7 (1.0) 3.7 (1.1) 0.97 0.54 15.0
VCO2 (L/min) 0.2 (0.1) 0.2 (0.1) 0.81 0.78 14.0
RER 0.8 (0.1) 0.8 (0.1) 0.38 0.86 3.2
VE (L/min) 8.3 (3.0) 8.0 (3.2) 0.80 0.75 13.6
VE/VCO2 31.8 (5.0) 31.2 (4.5) 0.68 0.86 4.3
BF 13.8 (3.4) 13.4 (3.2) 0.68 0.79 7.6
Stage 1 exercise (10 steps/minute)
VO2 (L/min) 0.7 (0.2) 0.7 (0.2) 0.81 0.46 14.8
VO2 (mL/kg/min) 10.4 (2.4) 9.9 (2.1) 0.41 0.51 11.2
VCO2 (L/min) 0.5 (0.2) 0.5 (0.2) 1.00 0.61 14.7
RER 0.7 (0.1) 0.7(0.1) 0.55 0.18 5.8
VE (L/min) 16.1 (4.7) 15.2 (5.2) 0.47 0.78 11.5
VE/VCO2 28.2 (2.8) 27.6 (2.6) 0.37 0.56 4.4
BF 18.3 (2.7) 17.3 (2.6) 0.16 0.49 9.1
Stage 2 exercise (15 steps/minute)
VO2 (L/min) 0.9 (0.2) 0.8 (0.2) 0.70 0.76 8.5
VO2 (mL/kg/min) 12.5 (2.2) 11.8 (2.6) 0.25 0.84 6.9
VCO2 (L/min) 0.7 (0.2) 0.6 (0.2) 0.47 0.79 10.7
RER 0.8 (0.1) 0.8 (0.0) 0.47 0.88 2.2
VE (L/min) 20.2 (7.4) 18.7 (6.1) 0.42 0.91 8.7
VE/VCO2 27.5 (2.7) 26.1 (2.3) 0.11 0.82 3.1
BF 18.9 (3.4) 17.3 (4.7) 0.17 0.77 6.7
BF, breathing frequency; CV, coefficient of variation; r, correlation
coefficient; RER, respiratory exchange ratio; VE, minute ventilation;
VE/VCO2, minute ventilation and carbon dioxide production; VCO2,
carbon dioxide release; VO2, oxygen consumption.
Data are expressed as mean (SD).
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reproducibility of the CORS test.23 Reproducibility of haemo-
dynamic measures at rest and their response to stress in
heart failure using a non-invasive gas rebreathing technology
has been previously reported.19 In post-cardiac surgery pa-
tients, the bioreactance method was validated against
thermodilution with a strong relationship reported between
the two methods.24 Myers et al. also found strong relation-
ships between peak cardiac index and peak oxygen consump-
tion when measured by direct Fick and bioreactance method
in patients with heart failure.25 At rest and in response to
stress exercise, the bioreactance method has previously dem-
onstrated good test–retest reliability for estimating cardiac
output.15 This further supports the use of the bioreactance
method and its integration into the CORS test to estimate car-
diac output at rest and in response to stress exercise as used
in the present study with the overall aim to improve diagno-
sis and monitoring of heart failure in primary care.
Cardiac index declines with age but does not differ be-
tween male and female healthy individuals.26 The same
study suggests that 50% of patients with heart failure re-
duced ejection fraction demonstrate reduced cardiac index
at rest compared with healthy controls.26 However, it ap-
pears that both heart failure patients with reduced as well
as preserved ejection fraction demonstrate diminished car-
diac output (cardiac index) in response to exercise-induced
stress.27–29
Data from the present study indicate reproducibility of
the CORS test as the relationship between repeated cardiac
output measures were strong. Similar strength of the rela-
tionship has been previously reported for bioreactance car-
diac outputs at rest and in response to maximal graded
cardiopulmonary exercise testing procedure.15 Bland–
Altman analyses for cardiac output and cardiac index dem-
onstrated low mean differences between Test 1 and Test 2
and acceptable limits of agreement for each stage of the
CORS test when all data were grouped together. A recent
comparison study between cardiac output estimated by
bioreactance and gas rebreathing during exercise recently
demonstrated acceptable limits of agreement between the
two methods.18
These findings suggest that the bioreactance method, as
used in the present study and integrated in the CORS test,
is a reliable method in estimating cardiac output at rest and
in response to stress exercise.
Meaning of the study: explanations and
implications for clinicians and policymakers
According to the most recent European Society of Cardiology
guideline, heart failure is presented with reduced cardiac out-
put at rest and/or in response to stress.1 Accordingly,
Figure 2 Mean cardiac output and cardiac index values and relationship between repeated cardiac output and cardiac index values: (A) mean cardiac
output for each stage of the cardiac output response to stress (CORS) test for Test 1 and Test 2; (B) mean cardiac index for each stage of the CORS test
for Test 1 and Test 2; (C) relationship between cardiac output at Test 1 and Test 2 when all data are grouped together (CORS test); (D) relationship
between cardiac index at Test 1 and Test 2 when all data are grouped together (CORS test).
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measurement of cardiac output not only at rest but particu-
larly during short stress, such as exercise, can help detect
heart failure. An accurate measure of cardiac output is essen-
tial for differentiating diagnosis in many clinical presentations
and specialities including anaesthesiology, emergency care,
and cardiology.16,30 Enhancing early diagnosis of heart failure
in primary care using the CORS as a ‘rule in’ test (to be per-
formed in natriuretic peptide positively tested patients) may
(i) reduce the number of inaccurate and expensive referrals
to secondary care, which worry patients, and (ii) improve pa-
tient quality and length of life and reduce the number of hos-
pital admissions as it will allow early administration of
evidenced-based proved to improve symptoms and
outcomes.1
Echocardiography (performed in secondary care) with car-
diology heart failure specialist review remains the reference
method for the diagnosis of heart failure.1,2 However, the
routine use of echocardiography in primary care setting is
limited due to time, required expertise, and facilities.31
Serum natriuretic peptide tests continue to be used as a ‘rule
out’ test to exclude heart failure in clinical practice, but re-
duced specificity and inconsistencies in optimal thresholds
lead to misdiagnosis and inaccurate and expensive referrals
from primary to secondary care.1,2,9,32
Unanswered questions and future research
Findings of the present study demonstrate acceptable repro-
ducibility of the CORS test to evaluate cardiac output at rest
and in response to exercise stress. Our ongoing research will
determine clinical (diagnostic accuracy) effectiveness and
cost-effectiveness of the CORS to be used as a ‘rule in’ test
in primary care to improve diagnosis and referral accuracy
of patients with suspected heart failure. Future implementa-
tion of the CORS in primary care will lead to improved length
and quality of life for patients and reduced number of inaccu-
rate and expensive referrals, which are worrying for patients.
Figure 3 Bland–Altman plots to demonstrate limits of agreement for cardiac output between Test 1 and Test 2 at each of four stages of the cardiac
output response to stress test, i.e. (A) at rest, (B) standing, and the 3 min stages of step exercise, (C) 10 steps per minute and (D) 15 steps per minute.
The solid line represents the mean difference, and the dashed lines represent lower and upper limits of agreement between Test 1 and Test 2.
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Figure 5 Bland–Altman plots to demonstrate limits of agreement between Test 1 and Test 2 for all stages of the cardiac output response to stress test:
(A) combined data for cardiac output and (B) combined data for cardiac index. The solid line represents the mean difference, and the dashed lines
represent lower and upper limits of agreement between Test 1 and Test 2.
Figure 4 Bland–Altman plots to demonstrate limits of agreement for cardiac index between Test 1 and Test 2 at each of the four stages of the cardiac
output response to stress test, i.e. (A) at rest, (B) standing, and the 3 min stages of step exercise, (C) 10 steps per minute and (D) 15 steps per minute.
The solid line represents the mean difference, and the dashed lines represent lower and upper limits of agreement between Test 1 and Test 2.
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The current National Institute for Clinical Excellence guideline
for diagnosis and management of heart failure in primary and
secondary care and clinical practice suggests that heart
failure as a final diagnosis is only confirmatory in only ~1/3
of patients suspected of having disease.2 Previous evidence
suggest that general practice records indicate that only 34%
of patients with an existing clinical label of heart failure had
diagnosis confirmed at echocardiography and specialist
review4 and that average waiting time for this investigation
was 67 days.33 However, early diagnosis of heart failure
improves short-term and long-term outcomes while reducing
the risk of hospital admissions by 23%.2 Considering poor
prognosis is consequential of a delayed diagnosis of heart
failure, and the lack of additional testing tools in primary care
to better identify cardiac dysfunction, it is reasonable to
suggest that the CORS test may have an important role within
primary care to improve diagnosis of heart failure and help
GPs monitor patients and their response to treatment.
Conclusions
The present study for the first time describes a novel, easy-
to-use, patient-friendly, non-invasive CORS test.Major findings
suggest acceptable reproducibility of the CORS test, which is
developed to potentially improve diagnosis and monitoring of
heart failure in primary care. Our ongoing research investigates
clinical effectiveness and cost-effectiveness of the CORS test to
be used by primary care physicians as a ‘rule in’ test to improve
diagnosis and monitoring of heart failure in primary care.
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